Drugs / VAX014
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05901285 | Nov 2023 → Aug 2027 expected | — | Vaxiion Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT03854721 | May 2019 → Mar 2023 | urothelial carcinoma | Vaxiion Therapeutics | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VAX014 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03854721 ↗ |
| Action | Deplete | “with the result being tumor cell lysis.” NCT03854721 ↗ |
| Modality | Other / unclassified | “VAX014 is a formulation of recombinant bacterial minicells” NCT03854721 ↗ |
| Route | Other | “VAX014 via a urinary catheter into the bladder” NCT03854721 ↗ |